[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Medical News & Perspectives
March 8, 2006

Medical Device Oversight Under Scrutiny

JAMA. 2006;295(10):1109-1110. doi:10.1001/jama.295.10.1109

The US Food and Drug Administration (FDA) announced it has initiated a process aimed at improving patient safety through better postmarketing oversight of medical devices—an action that comes in the midst of some high-profile reports of recall notices, subpoenas, and corporate warning letters about problematic cardiac devices.

At a January 20 press conference, the FDA's Center for Devices and Radiological Health launched an initiative to improve safety monitoring of medical devices after they reach the market, by creating a regulatory environment that enables investigators to move more quickly to identify, analyze, and act when medical device problems surface. Daniel Schultz, MD, the center's director, said the announcement came after about one year's work.